Physician profile
Travis Groth
NPI 1528351657
$2,235.71
in general payments reported to CMS, 2019-2025
23 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $171 · 2021: $252 · 2022: $99.63 · 2023: $177 · 2024: $343 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.17 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $360.38 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $313.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $160.36 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Access Pro Medical, LLC | $150.00 | 2025 | Matriderm |
| Janssen Pharmaceuticals, INC | $90.73 | 2019 | |
| Osiris Therapeutics INC. | $76.67 | 2019 | |
| Esperion Therapeutics, INC. | $74.64 | 2021 | |
| Glaxosmithkline, LLC. | $67.35 | 2022-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $61.45 | 2023-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $50.32 | 2021-2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $44.00 | 2020-2021 | |
| Amgen INC. | $43.45 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.90 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $31.34 | 2020-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.71 | 2024 | |
| Exact Sciences Corporation | $29.19 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.57 | 2024-2025 | Gardasil 9, Gardasil, Vaxneuvance |
| Globus Medical, INC. | $27.52 | 2025 | Senza |
| Genentech USA, INC. | $20.89 | 2020 | |
| Nevro Corp. | $16.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2025 | Eliquis |
| Medtronic Vascular, INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Groth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.